Company intelligence / Profile preview

Intensity Solutions

Shelton, Connecticut, United Statesconsultintensity.com ↗

Ownership: Private
Employees: ~7
Development stage: Other

Overview

INT230‑6, the lead product candidate, has demonstrated tumor killing and induction of adaptive immune responses in over 200 patients across multiple clinical studies. Completed Phase 1/2 dose escalation study in metastatic cancers, a randomized Phase 2 trial in locally advanced breast cancer, and initiated a pivotal Phase 3 trial in soft tissue sarcoma. Early results show potential to convert deadly cancers into chronic diseases even when conventional immunotherapy fails.

Therapeutic areas: Oncology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

MerckBristol Myers SquibbNational Institutes of HealthSwiss Group for Clinical Cancer Research SAKK

Beyond the preview

Go deeper on Intensity Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intensity Solutions.

Explore the full profile